Rizvi, Naiyer A <br/><br/>
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  09 2016 
 - 2969-79 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2016.66.9861  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>B7-H1 Antigen--biosynthesis<br/>Carboplatin--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cisplatin--administration & dosage<br/>Cohort Studies<br/>Deoxycytidine--administration & dosage<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>ErbB Receptors--genetics<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Nivolumab<br/>Pemetrexed--administration & dosage<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Survival Rate<br/>Gemcitabine